Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439746 | 0.86 | LMNA (0.45) | ALDH1A1LMNACYP1A2CYP2C9PLA2G1B | |
| SCHEMBL3676819 | 0.86 | LMNA (0.45) | ALDH1A1LMNACYP1A2CYP2C9PLA2G1B | |
| SCHEMBL23534358 | 0.81 | ALDH1A1 (0.44) | ALDH1A1LMNACYP1A2CYP2C9PLA2G1B | |
| SCHEMBL27695116 | 0.80 | ALDH1A1 (0.45) | ALDH1A1LMNACYP1A2CYP2C9MAPT | |
| SCHEMBL30731578 | 0.80 | LMNA (0.44) | ALDH1A1LMNACYP1A2CYP2C9PLA2G1B | |
| SCHEMBL23969551 | 0.80 | LMNA (0.44) | ALDH1A1LMNACYP1A2CYP2C9PLA2G1B | |
| SCHEMBL13706557 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNACYP1A2CYP2C9PLA2G1B | |
| SCHEMBL31463754 | 0.79 | LMNA (0.40) | ALDH1A1LMNACYP1A2CYP2C9PLA2G1B | |
| SCHEMBL31054705 | 0.79 | LMNA (0.40) | ALDH1A1LMNACYP1A2CYP2C9PLA2G1B | |
| SCHEMBL18526265 | 0.79 | ELANE (0.47) | ALDH1A1LMNACYP1A2CYP2C9PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-27 | — | — | US | disclosed |
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | PCSK9, LIPA, ACSL3 | ALDH1A1 3656/4885LMNA 1581/4885CYP1A2 3236/4885 |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | PCSK9, PCSK7, PCSK6 | ALDH1A1 3619/4885LMNA 2126/4885CYP1A2 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.